NCT03455556View on ClinicalTrials.gov

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 10, 2018

Primary Completion Date

September 11, 2019

Study Completion Date

January 7, 2020

Conditions
Mesothelin PositiveStage III Non-Small Cell Lung Cancer AJCC v7Stage IIIA Non-Small Cell Lung Cancer AJCC v7Stage IIIB Non-Small Cell Lung Cancer AJCC v7Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
BIOLOGICAL

Anetumab Ravtansine

Given IV

BIOLOGICAL

Atezolizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (3)

55905

Mayo Clinic, Rochester

85054

Mayo Clinic Hospital, Phoenix

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER